Francesca Zammarchi

Francesca Zammarchi

Company: ADC Therapeutics

Job title: Head of Pharmacology

Seminars:

Live Discussion & Question Time 9:40 am

Read more

day: Day One

Novel Application of a CD25-Targeted, Pyrrolobenzodiazepine (PBD) Dimer-Based ADC as Immunotherapeutic Agent 9:00 am

Currently, ADCs are predominantly used to directly target antigen-positive tumour cells This presentation will provide proof-of-concept for a novel application of a CD25-targeted, PBD-based ADC as immunotherapeutic agent, since the main mode of action relies on the ADC directly targeting T regulatory immune cells, rather than tumour cells Additional data will be presented showing promising…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.